Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Fusion protein | 1 |
Top 5 Target | Count |
---|---|
ACE2(Angiotensin-converting enzyme 2) | 1 |
Target |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MTMR14 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NRP-1 modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2023 |
Sponsor / Collaborator [+3] |
Start Date29 Aug 2019 |
Sponsor / Collaborator |
Start Date01 Jan 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
WO2022167947 ( ACE2 ) | Infectious Diseases More | Discovery |
AUTEN-99 ( MTMR14 ) | Huntington Disease More | Pending |
NRP-1 modulators(Eötvös Loránd University) ( NRP-1 ) | Neoplasms More | Pending |